Literature DB >> 16466273

What value health?: A review of health state values used in early technology assessments for NICE.

Ken Stein1, Alison Fry, Ali Round, Ruairidh Milne, John Brazier.   

Abstract

The objective of this article was to review the methods used to obtain quality-of-life (utility) weights reported in assessments carried out for the National Institute for Health and Clinical Excellence (NICE).The design of the review was a cross-sectional survey. Health technology assessment (HTA) reports published on the NICE website up to May 2003 were reviewed. Data were extracted on the following: the approach to utility estimation (direct or indirect), how health states were described for indirect estimation, valuation techniques used (standard gamble [SG], time trade-off [TTO], visual analogue scale [VAS], etc.), whether uncertainty in utility estimates was explored in cost-utility analyses, and whether utility values were identified as a priority for further research by assessment authors.Fifty-six assessments were reviewed, of which 28 reported 45 cost-utility analyses. There was striking variation in the values used to describe different health states. Data from patients were used in 15 (33%) analyses, from the general public in 10 (22%) and from clinicians in 4 (9%). In 16 (36%) cases, the source for utility estimates was unclear. Health states were described using a range of generic and disease-specific measures, although the EQ-5D was used most frequently. In 25 analyses (56%), the valuation technique used was not reported. TTO was used in 11 (24%), SG in 3 (7%), magnitude estimation in 5 (11%) and VAS in 1 (2%). Sensitivity analyses based on utility values were reported in 25 cases (56%), more commonly in reports of analyses carried out by independent teams than technology sponsors although this may be subject to reporting bias. Further research into quality of life was recommended in 17 (61%) of the 28 assessment reports that contained at least one cost-utility analysis. Greater transparency and consistency are required in reporting the methods used to obtain quality-of-life weights in cost-utility analyses, and better sources of data are required. Methodological variation results in important differences in values. Therefore, caution must be exercised when comparing the results of different cost-utility analyses.

Entities:  

Mesh:

Year:  2005        PMID: 16466273     DOI: 10.2165/00148365-200504040-00004

Source DB:  PubMed          Journal:  Appl Health Econ Health Policy        ISSN: 1175-5652            Impact factor:   2.561


  12 in total

1.  Time trade-off and attitudes toward euthanasia: implications of using 'death' as an anchor in health state valuation.

Authors:  Liv A Augestad; Kim Rand-Hendriksen; Knut Stavem; Ivar Sønbø Kristiansen
Journal:  Qual Life Res       Date:  2012-06-08       Impact factor: 4.147

2.  A forgotten aspect of the NICE reference case: an observational study of the health related quality of life impact on caregivers of people with multiple sclerosis.

Authors:  Sarah Acaster; Rodolphe Perard; Deven Chauhan; Andrew J Lloyd
Journal:  BMC Health Serv Res       Date:  2013-09-09       Impact factor: 2.655

3.  Preoperative risk assessment for bleeding and thromboembolism.

Authors:  Donald M Arnold; Julia Anderson; Clive Kearon
Journal:  BMJ       Date:  2009-09-03

4.  The use of QALY weights for QALY calculations: a review of industry submissions requesting listing on the Australian Pharmaceutical Benefits Scheme 2002-4.

Authors:  Paul A Scuffham; Jennifer A Whitty; Andrew Mitchell; Rosalie Viney
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

5.  Utilities and disutilities for attributes of injectable treatments for type 2 diabetes.

Authors:  Kristina S Boye; Louis S Matza; Kimberly N Walter; Kate Van Brunt; Andrew C Palsgrove; Aodan Tynan
Journal:  Eur J Health Econ       Date:  2010-03-12

6.  Quality of life implications of bisphosphonate-associated osteonecrosis of the jaw.

Authors:  Rebecca Anne Miksad; Kuan-Chi Lai; Thomas Benton Dodson; Sook-Bin Woo; Nathaniel Simon Treister; Omosalewa Akinyemi; Marian Bihrle; Guy Maytal; Meredith August; G Scott Gazelle; J Shannon Swan
Journal:  Oncologist       Date:  2011-01-06

7.  Utilities and disutilities for type 2 diabetes treatment-related attributes.

Authors:  Louis S Matza; Kristina S Boye; Nicole Yurgin; Jessica Brewster-Jordan; Sally Mannix; Jodi M Shorr; Beth L Barber
Journal:  Qual Life Res       Date:  2007-07-19       Impact factor: 4.147

8.  Health Preference Measures in Patients with Obstructive Sleep Apnea Syndrome Undergoing Continuous Positive Airway Pressure Therapy: Data from a Randomized Trial.

Authors:  Fabienne L Huber; Michael Furian; Malcolm Kohler; Tsogyal D Latshang; Yvonne Nussbaumer-Ochsner; Alexander Turk; Otto D Schoch; Irene Laube; Robert Thurnheer; Konrad E Bloch
Journal:  Respiration       Date:  2021-02-04       Impact factor: 3.580

9.  A pilot Internet "value of health" panel: recruitment, participation and compliance.

Authors:  Ken Stein; Matthew Dyer; Tania Crabb; Ruairidh Milne; Alison Round; Julie Ratcliffe; John Brazier
Journal:  Health Qual Life Outcomes       Date:  2006-11-27       Impact factor: 3.186

Review 10.  Review of studies mapping from quality of life or clinical measures to EQ-5D: an online database.

Authors:  Helen Dakin
Journal:  Health Qual Life Outcomes       Date:  2013-09-05       Impact factor: 3.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.